AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals
Identifieur interne : 001315 ( Istex/Corpus ); précédent : 001314; suivant : 001316AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals
Auteurs : J. P. C. Consignado ; C. Macapagal ; S. V. NavarraSource :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
English descriptors
- Teeft :
- Autoimmune diseases, Combination therapy, Corticosteroid therapy, Cumulative prednisone dose, Damage accrual, Disclosure, Disease activity, Erythematosus, Fetal wastage, Flare, Gran canaria, Important role, Intravenous cyclophosphamide, Irreversible organ damage, Japan background, Limited evidence, Lupus, Lupus nephritis, Maintenance phase, Medical center, Oral prednisone, Outcome measures, Pregnant women, Prospective study, Rheumatoid arthritis, Rituximab, Rituximab treatment, Santo tomas, Scientific abstracts, Spanish society, Systematic review, Systemic, Systemic lupus erythematosus, Tertiary hospitals, Thrombotic thrombocytopenic purpura.
Abstract
Objectives: Objective The study aims to describe the prevalence of end-organ damage in a cohort of systemic lupus erythematosus (SLE) patients at two tertiary hospitals and determine any association of SLE manifestations, medications and end-organ damage. Methods: Design Data of adult (≥18 years old) patients seen at the lupus clinics of two tertiary hospitals (University of Santo Tomas, St. Luke’s Medical Center) from January to June 2012 was assessed using the Systemic Lupus International Collaborating Clinics/SLE Damage Index (SLICC/SDI). Medical records were reviewed for SLE characteristics, American College of Rheumatology (ACR) presenting manifestations of SLE, cumulative steroid dose, and immunosuppressive agents. T test, Fisher’s Exact test, univariate and multivariate analysis were utilized for data analysis. Results: Results. 187 SLE patients (177, 94.7% females), with mean age at diagnosis at 29±10.75 years and mean disease duration of 9±6.7 years were included in the study. 108 (57.7%) had at least 1 end-organ damage. Common end-organ damage were steroid-induced cataract, proteinuria, and stroke in 25 (23%), 22 (20%), and 14 (13%) patients respectively. Damage occurred at an average of 6.6 years after diagnosis. Development of subsequent end-organ damage occurred at an average of 3 years after the preceding damage. Presenting manifestations at SLE diagnosis of proteinuria (p=0.024), anemia (p=0.028), and thrombocytopenia (p=0.049) and immunosuppressive treatment with cyclophosphamide (p=0.046) and cumulative prednisone dose of more than 10 grams (p=0.043) were significantly associated with damage. Conclusions: Conclusion. In this cohort of SLE patients, majority were found to have at least one end-organ damage, most commonly steroid-induced cataract, proteinuria, and stroke. Presenting manifestations of proteinuria, anemia, and thrombocytopenia were significantly associated with damage, reflecting a high disease activity that required increased doses of glucocorticoids. Of the therapies, cylophosphamide and a cumulative prednisone dose ≥ 10 grams were significantly associated with development of end-organ damage. Disclosure of Interest None Declared
Url:
DOI: 10.1136/annrheumdis-2013-eular.2696
Links to Exploration step
ISTEX:D7A53D6078DBDF33541E5A73A1A49B488BC70DDCLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals</title><author><name sortKey="Consignado, J P C" sort="Consignado, J P C" uniqKey="Consignado J" first="J. P. C." last="Consignado">J. P. C. Consignado</name><affiliation><mods:affiliation>Rheumatology, St. Luke’s Medical Center, Quezon City</mods:affiliation></affiliation><affiliation><mods:affiliation>Rheumatology, St. Luke’s Medical Center, Quezon City</mods:affiliation></affiliation></author><author><name sortKey="Macapagal, C" sort="Macapagal, C" uniqKey="Macapagal C" first="C." last="Macapagal">C. Macapagal</name><affiliation><mods:affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</mods:affiliation></affiliation><affiliation><mods:affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</mods:affiliation></affiliation></author><author><name sortKey="Navarra, S V" sort="Navarra, S V" uniqKey="Navarra S" first="S. V." last="Navarra">S. V. Navarra</name><affiliation><mods:affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</mods:affiliation></affiliation><affiliation><mods:affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D7A53D6078DBDF33541E5A73A1A49B488BC70DDC</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/annrheumdis-2013-eular.2696</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-BKNCHRHM-0/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001315</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001315</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals</title><author><name sortKey="Consignado, J P C" sort="Consignado, J P C" uniqKey="Consignado J" first="J. P. C." last="Consignado">J. P. C. Consignado</name><affiliation><mods:affiliation>Rheumatology, St. Luke’s Medical Center, Quezon City</mods:affiliation></affiliation><affiliation><mods:affiliation>Rheumatology, St. Luke’s Medical Center, Quezon City</mods:affiliation></affiliation></author><author><name sortKey="Macapagal, C" sort="Macapagal, C" uniqKey="Macapagal C" first="C." last="Macapagal">C. Macapagal</name><affiliation><mods:affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</mods:affiliation></affiliation><affiliation><mods:affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</mods:affiliation></affiliation></author><author><name sortKey="Navarra, S V" sort="Navarra, S V" uniqKey="Navarra S" first="S. V." last="Navarra">S. V. Navarra</name><affiliation><mods:affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</mods:affiliation></affiliation><affiliation><mods:affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-06">2013-06</date><biblScope unit="volume">72</biblScope><biblScope unit="issue">Suppl 3</biblScope><biblScope unit="page" from="A901">A901</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Autoimmune diseases</term><term>Combination therapy</term><term>Corticosteroid therapy</term><term>Cumulative prednisone dose</term><term>Damage accrual</term><term>Disclosure</term><term>Disease activity</term><term>Erythematosus</term><term>Fetal wastage</term><term>Flare</term><term>Gran canaria</term><term>Important role</term><term>Intravenous cyclophosphamide</term><term>Irreversible organ damage</term><term>Japan background</term><term>Limited evidence</term><term>Lupus</term><term>Lupus nephritis</term><term>Maintenance phase</term><term>Medical center</term><term>Oral prednisone</term><term>Outcome measures</term><term>Pregnant women</term><term>Prospective study</term><term>Rheumatoid arthritis</term><term>Rituximab</term><term>Rituximab treatment</term><term>Santo tomas</term><term>Scientific abstracts</term><term>Spanish society</term><term>Systematic review</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Tertiary hospitals</term><term>Thrombotic thrombocytopenic purpura</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Objectives: Objective The study aims to describe the prevalence of end-organ damage in a cohort of systemic lupus erythematosus (SLE) patients at two tertiary hospitals and determine any association of SLE manifestations, medications and end-organ damage. Methods: Design Data of adult (≥18 years old) patients seen at the lupus clinics of two tertiary hospitals (University of Santo Tomas, St. Luke’s Medical Center) from January to June 2012 was assessed using the Systemic Lupus International Collaborating Clinics/SLE Damage Index (SLICC/SDI). Medical records were reviewed for SLE characteristics, American College of Rheumatology (ACR) presenting manifestations of SLE, cumulative steroid dose, and immunosuppressive agents. T test, Fisher’s Exact test, univariate and multivariate analysis were utilized for data analysis. Results: Results. 187 SLE patients (177, 94.7% females), with mean age at diagnosis at 29±10.75 years and mean disease duration of 9±6.7 years were included in the study. 108 (57.7%) had at least 1 end-organ damage. Common end-organ damage were steroid-induced cataract, proteinuria, and stroke in 25 (23%), 22 (20%), and 14 (13%) patients respectively. Damage occurred at an average of 6.6 years after diagnosis. Development of subsequent end-organ damage occurred at an average of 3 years after the preceding damage. Presenting manifestations at SLE diagnosis of proteinuria (p=0.024), anemia (p=0.028), and thrombocytopenia (p=0.049) and immunosuppressive treatment with cyclophosphamide (p=0.046) and cumulative prednisone dose of more than 10 grams (p=0.043) were significantly associated with damage. Conclusions: Conclusion. In this cohort of SLE patients, majority were found to have at least one end-organ damage, most commonly steroid-induced cataract, proteinuria, and stroke. Presenting manifestations of proteinuria, anemia, and thrombocytopenia were significantly associated with damage, reflecting a high disease activity that required increased doses of glucocorticoids. Of the therapies, cylophosphamide and a cumulative prednisone dose ≥ 10 grams were significantly associated with development of end-organ damage. Disclosure of Interest None Declared</div></front></TEI><istex><corpusName>bmj</corpusName><keywords><teeft><json:string>lupus</json:string><json:string>rituximab</json:string><json:string>erythematosus</json:string><json:string>systemic lupus erythematosus</json:string><json:string>combination therapy</json:string><json:string>disease activity</json:string><json:string>lupus nephritis</json:string><json:string>damage accrual</json:string><json:string>oral prednisone</json:string><json:string>tertiary hospitals</json:string><json:string>maintenance phase</json:string><json:string>rheumatoid arthritis</json:string><json:string>autoimmune diseases</json:string><json:string>systematic review</json:string><json:string>systemic</json:string><json:string>scientific abstracts</json:string><json:string>limited evidence</json:string><json:string>irreversible organ damage</json:string><json:string>important role</json:string><json:string>prospective study</json:string><json:string>fetal wastage</json:string><json:string>corticosteroid therapy</json:string><json:string>medical center</json:string><json:string>santo tomas</json:string><json:string>cumulative prednisone dose</json:string><json:string>spanish society</json:string><json:string>gran canaria</json:string><json:string>outcome measures</json:string><json:string>intravenous cyclophosphamide</json:string><json:string>rituximab treatment</json:string><json:string>thrombotic thrombocytopenic purpura</json:string><json:string>japan background</json:string><json:string>pregnant women</json:string><json:string>disclosure</json:string><json:string>flare</json:string></teeft></keywords><author><json:item><name>J. P. C. Consignado</name><affiliations><json:string>Rheumatology, St. Luke’s Medical Center, Quezon City</json:string><json:string>Rheumatology, St. Luke’s Medical Center, Quezon City</json:string></affiliations></json:item><json:item><name>C. Macapagal</name><affiliations><json:string>Rheumatology, University of Santo Tomas, Manila, Philippines</json:string><json:string>Rheumatology, University of Santo Tomas, Manila, Philippines</json:string></affiliations></json:item><json:item><name>S. V. Navarra</name><affiliations><json:string>Rheumatology, University of Santo Tomas, Manila, Philippines</json:string><json:string>Rheumatology, University of Santo Tomas, Manila, Philippines</json:string></affiliations></json:item></author><articleId><json:string>annrheumdis-2013-eular.2696</json:string></articleId><arkIstex>ark:/67375/NVC-BKNCHRHM-0</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>abstract</json:string></originalGenre><abstract>Objectives: Objective The study aims to describe the prevalence of end-organ damage in a cohort of systemic lupus erythematosus (SLE) patients at two tertiary hospitals and determine any association of SLE manifestations, medications and end-organ damage. Methods: Design Data of adult (≥18 years old) patients seen at the lupus clinics of two tertiary hospitals (University of Santo Tomas, St. Luke’s Medical Center) from January to June 2012 was assessed using the Systemic Lupus International Collaborating Clinics/SLE Damage Index (SLICC/SDI). Medical records were reviewed for SLE characteristics, American College of Rheumatology (ACR) presenting manifestations of SLE, cumulative steroid dose, and immunosuppressive agents. T test, Fisher’s Exact test, univariate and multivariate analysis were utilized for data analysis. Results: Results. 187 SLE patients (177, 94.7% females), with mean age at diagnosis at 29±10.75 years and mean disease duration of 9±6.7 years were included in the study. 108 (57.7%) had at least 1 end-organ damage. Common end-organ damage were steroid-induced cataract, proteinuria, and stroke in 25 (23%), 22 (20%), and 14 (13%) patients respectively. Damage occurred at an average of 6.6 years after diagnosis. Development of subsequent end-organ damage occurred at an average of 3 years after the preceding damage. Presenting manifestations at SLE diagnosis of proteinuria (p=0.024), anemia (p=0.028), and thrombocytopenia (p=0.049) and immunosuppressive treatment with cyclophosphamide (p=0.046) and cumulative prednisone dose of more than 10 grams (p=0.043) were significantly associated with damage. Conclusions: Conclusion. In this cohort of SLE patients, majority were found to have at least one end-organ damage, most commonly steroid-induced cataract, proteinuria, and stroke. Presenting manifestations of proteinuria, anemia, and thrombocytopenia were significantly associated with damage, reflecting a high disease activity that required increased doses of glucocorticoids. Of the therapies, cylophosphamide and a cumulative prednisone dose ≥ 10 grams were significantly associated with development of end-organ damage. Disclosure of Interest None Declared</abstract><qualityIndicators><score>7.616</score><pdfWordCount>2616</pdfWordCount><pdfCharCount>17736</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>2</pdfPageCount><pdfPageSize>594.72 x 841.68 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>303</abstractWordCount><abstractCharCount>2199</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals</title><genre><json:string>abstract</json:string></genre><host><title>Annals of the Rheumatic Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0003-4967</json:string></issn><eissn><json:string>1468-2060</json:string></eissn><publisherId><json:string>ard</json:string></publisherId><volume>72</volume><issue>Suppl 3</issue><pages><first>A901</first></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2013</json:string></date><geogName></geogName><orgName></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName></persName><placeName></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/NVC-BKNCHRHM-0</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - rheumatology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - arthritis & rheumatology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - General Biochemistry, Genetics and Molecular Biology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1136/annrheumdis-2013-eular.2696</json:string></doi><id>D7A53D6078DBDF33541E5A73A1A49B488BC70DDC</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-BKNCHRHM-0/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-BKNCHRHM-0/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/NVC-BKNCHRHM-0/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://publisher-list.data.istex.fr">BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><availability><licence><p>© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</p></availability><date>2013</date></publicationStmt><notesStmt><note type="abstract" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-HPN7T1Q2-R">abstract</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals</title><author xml:id="author-0000"><persName><forename type="first">J. P. C.</forename><surname>Consignado</surname></persName><affiliation>Rheumatology, St. Luke’s Medical Center, Quezon City</affiliation><affiliation>Rheumatology, St. Luke’s Medical Center, Quezon City</affiliation></author><author xml:id="author-0001"><persName><forename type="first">C.</forename><surname>Macapagal</surname></persName><affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</affiliation><affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</affiliation></author><author xml:id="author-0002"><persName><forename type="first">S. V.</forename><surname>Navarra</surname></persName><affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</affiliation><affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</affiliation></author><idno type="istex">D7A53D6078DBDF33541E5A73A1A49B488BC70DDC</idno><idno type="ark">ark:/67375/NVC-BKNCHRHM-0</idno><idno type="DOI">10.1136/annrheumdis-2013-eular.2696</idno><idno type="href">annrheumdis-72-A901-3.pdf</idno><idno type="article-id">annrheumdis-2013-eular.2696</idno><idno type="local">annrheumdis;72/Suppl_3/A901-c</idno></analytic><monogr><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="pISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><idno type="publisher-id">ard</idno><idno type="PublisherID-hwp">annrheumdis</idno><idno type="PublisherID-nlm-ta">Ann Rheum Dis</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-06"></date><biblScope unit="volume">72</biblScope><biblScope unit="issue">Suppl 3</biblScope><biblScope unit="page" from="A901">A901</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2013</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Objectives: Objective The study aims to describe the prevalence of end-organ damage in a cohort of systemic lupus erythematosus (SLE) patients at two tertiary hospitals and determine any association of SLE manifestations, medications and end-organ damage. Methods: Design Data of adult (≥18 years old) patients seen at the lupus clinics of two tertiary hospitals (University of Santo Tomas, St. Luke’s Medical Center) from January to June 2012 was assessed using the Systemic Lupus International Collaborating Clinics/SLE Damage Index (SLICC/SDI). Medical records were reviewed for SLE characteristics, American College of Rheumatology (ACR) presenting manifestations of SLE, cumulative steroid dose, and immunosuppressive agents. T test, Fisher’s Exact test, univariate and multivariate analysis were utilized for data analysis. Results: Results. 187 SLE patients (177, 94.7% females), with mean age at diagnosis at 29±10.75 years and mean disease duration of 9±6.7 years were included in the study. 108 (57.7%) had at least 1 end-organ damage. Common end-organ damage were steroid-induced cataract, proteinuria, and stroke in 25 (23%), 22 (20%), and 14 (13%) patients respectively. Damage occurred at an average of 6.6 years after diagnosis. Development of subsequent end-organ damage occurred at an average of 3 years after the preceding damage. Presenting manifestations at SLE diagnosis of proteinuria (p=0.024), anemia (p=0.028), and thrombocytopenia (p=0.049) and immunosuppressive treatment with cyclophosphamide (p=0.046) and cumulative prednisone dose of more than 10 grams (p=0.043) were significantly associated with damage. Conclusions: Conclusion. In this cohort of SLE patients, majority were found to have at least one end-organ damage, most commonly steroid-induced cataract, proteinuria, and stroke. Presenting manifestations of proteinuria, anemia, and thrombocytopenia were significantly associated with damage, reflecting a high disease activity that required increased doses of glucocorticoids. Of the therapies, cylophosphamide and a cumulative prednisone dose ≥ 10 grams were significantly associated with development of end-organ damage. Disclosure of Interest None Declared</p></abstract></profileDesc><revisionDesc><change when="2013-06">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2017-10-17">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-BKNCHRHM-0/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="abstract" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="hwp">annrheumdis</journal-id><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-id journal-id-type="publisher-id">ard</journal-id><journal-title>Annals of the Rheumatic Diseases</journal-title><abbrev-journal-title abbrev-type="publisher">Ann Rheum Dis</abbrev-journal-title><abbrev-journal-title>Ann Rheum Dis</abbrev-journal-title><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">annrheumdis-2013-eular.2696</article-id><article-id pub-id-type="doi">10.1136/annrheumdis-2013-eular.2696</article-id><article-id pub-id-type="other">annrheumdis;72/Suppl_3/A901-c</article-id><article-id pub-id-type="other">annrheumdis;annrheumdis-2013-eular.2696</article-id><article-id pub-id-type="other">A901.3</article-id><article-id pub-id-type="other">annrheumdis-2013-eular.2696</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts accepted for publication</subject><subj-group subj-group-type="heading"><subject>SLE, Sjögren’s and APS - treatment</subject></subj-group></subj-group></article-categories><title-group><article-title>AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Consignado</surname><given-names>J. P. C.</given-names></name><xref ref-type="aff" rid="AF00001"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Macapagal</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="AF00002"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Navarra</surname><given-names>S. V.</given-names></name><xref ref-type="aff" rid="AF00002"><sup>2</sup></xref></contrib></contrib-group><aff id="AF00001"><sup>1</sup>Rheumatology, St. Luke’s Medical Center, Quezon City</aff><aff id="AF00002"><sup>2</sup>Rheumatology, University of Santo Tomas, Manila, Philippines</aff><pub-date pub-type="ppub"><month>6</month><year>2013</year></pub-date><volume>72</volume><volume-id pub-id-type="other">72</volume-id><volume-id pub-id-type="other">72</volume-id><issue>Suppl 3</issue><issue-id pub-id-type="other">annrheumdis;72/Suppl_3</issue-id><issue-id pub-id-type="other" content-type="supplement">Suppl_3</issue-id><issue-id pub-id-type="other">72/Suppl_3</issue-id><issue-title>Annual European Congress of Rheumatology EULAR abstracts 2013, 12–15 June 2013, Spain</issue-title><fpage seq="3">A901</fpage><permissions><copyright-statement>© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2013</copyright-year></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="annrheumdis-72-A901-3.pdf"></self-uri><abstract><sec><title>Objectives: Objective</title><p>The study aims to describe the prevalence of end-organ damage in a cohort of systemic lupus erythematosus (SLE) patients at two tertiary hospitals and determine any association of SLE manifestations, medications and end-organ damage.</p></sec><sec><title>Methods: Design</title><p>Data of adult (≥18 years old) patients seen at the lupus clinics of two tertiary hospitals (University of Santo Tomas, St. Luke’s Medical Center) from January to June 2012 was assessed using the Systemic Lupus International Collaborating Clinics/SLE Damage Index (SLICC/SDI). Medical records were reviewed for SLE characteristics, American College of Rheumatology (ACR) presenting manifestations of SLE, cumulative steroid dose, and immunosuppressive agents. T test, Fisher’s Exact test, univariate and multivariate analysis were utilized for data analysis.</p><p><bold>Results: Results.</bold> 187 SLE patients (177, 94.7% females), with mean age at diagnosis at 29±10.75 years and mean disease duration of 9±6.7 years were included in the study. 108 (57.7%) had at least 1 end-organ damage. Common end-organ damage were steroid-induced cataract, proteinuria, and stroke in 25 (23%), 22 (20%), and 14 (13%) patients respectively. Damage occurred at an average of 6.6 years after diagnosis. Development of subsequent end-organ damage occurred at an average of 3 years after the preceding damage. Presenting manifestations at SLE diagnosis of proteinuria (<italic>p=0.024</italic>), anemia (<italic>p=0.028</italic>), and thrombocytopenia (<italic>p=0.049</italic>) and immunosuppressive treatment with cyclophosphamide <italic>(p=0.046)</italic> and cumulative prednisone dose of more than 10 grams <italic>(p=0.043)</italic> were significantly associated with damage.</p><p><bold>Conclusions: Conclusion.</bold> In this cohort of SLE patients, majority were found to have at least one end-organ damage, most commonly steroid-induced cataract, proteinuria, and stroke. Presenting manifestations of proteinuria, anemia, and thrombocytopenia were significantly associated with damage, reflecting a high disease activity that required increased doses of glucocorticoids. Of the therapies, cylophosphamide and a cumulative prednisone dose ≥ 10 grams were significantly associated with development of end-organ damage.</p></sec><sec><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals</title></titleInfo><name type="personal"><namePart type="given">J. P. C.</namePart><namePart type="family">Consignado</namePart><affiliation>Rheumatology, St. Luke’s Medical Center, Quezon City</affiliation><affiliation>Rheumatology, St. Luke’s Medical Center, Quezon City</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Macapagal</namePart><affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</affiliation><affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. V.</namePart><namePart type="family">Navarra</namePart><affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</affiliation><affiliation>Rheumatology, University of Santo Tomas, Manila, Philippines</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="abstract" displayLabel="abstract" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-HPN7T1Q2-R">abstract</genre><originInfo><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><dateIssued encoding="w3cdtf">2013-06</dateIssued><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract>Objectives: Objective The study aims to describe the prevalence of end-organ damage in a cohort of systemic lupus erythematosus (SLE) patients at two tertiary hospitals and determine any association of SLE manifestations, medications and end-organ damage. Methods: Design Data of adult (≥18 years old) patients seen at the lupus clinics of two tertiary hospitals (University of Santo Tomas, St. Luke’s Medical Center) from January to June 2012 was assessed using the Systemic Lupus International Collaborating Clinics/SLE Damage Index (SLICC/SDI). Medical records were reviewed for SLE characteristics, American College of Rheumatology (ACR) presenting manifestations of SLE, cumulative steroid dose, and immunosuppressive agents. T test, Fisher’s Exact test, univariate and multivariate analysis were utilized for data analysis. Results: Results. 187 SLE patients (177, 94.7% females), with mean age at diagnosis at 29±10.75 years and mean disease duration of 9±6.7 years were included in the study. 108 (57.7%) had at least 1 end-organ damage. Common end-organ damage were steroid-induced cataract, proteinuria, and stroke in 25 (23%), 22 (20%), and 14 (13%) patients respectively. Damage occurred at an average of 6.6 years after diagnosis. Development of subsequent end-organ damage occurred at an average of 3 years after the preceding damage. Presenting manifestations at SLE diagnosis of proteinuria (p=0.024), anemia (p=0.028), and thrombocytopenia (p=0.049) and immunosuppressive treatment with cyclophosphamide (p=0.046) and cumulative prednisone dose of more than 10 grams (p=0.043) were significantly associated with damage. Conclusions: Conclusion. In this cohort of SLE patients, majority were found to have at least one end-organ damage, most commonly steroid-induced cataract, proteinuria, and stroke. Presenting manifestations of proteinuria, anemia, and thrombocytopenia were significantly associated with damage, reflecting a high disease activity that required increased doses of glucocorticoids. Of the therapies, cylophosphamide and a cumulative prednisone dose ≥ 10 grams were significantly associated with development of end-organ damage. Disclosure of Interest None Declared</abstract><relatedItem type="host"><titleInfo><title>Annals of the Rheumatic Diseases</title></titleInfo><titleInfo type="abbreviated"><title>Ann Rheum Dis</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0003-4967</identifier><identifier type="eISSN">1468-2060</identifier><identifier type="PublisherID">ard</identifier><identifier type="PublisherID-hwp">annrheumdis</identifier><identifier type="PublisherID-nlm-ta">Ann Rheum Dis</identifier><part><date>2013</date><detail type="title"><title>Annual European Congress of Rheumatology EULAR abstracts 2013, 12–15 June 2013, Spain</title></detail><detail type="volume"><caption>vol.</caption><number>72</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 3</number></detail><extent unit="pages"><start>A901</start></extent></part></relatedItem><identifier type="istex">D7A53D6078DBDF33541E5A73A1A49B488BC70DDC</identifier><identifier type="ark">ark:/67375/NVC-BKNCHRHM-0</identifier><identifier type="DOI">10.1136/annrheumdis-2013-eular.2696</identifier><identifier type="href">annrheumdis-72-A901-3.pdf</identifier><identifier type="ArticleID">annrheumdis-2013-eular.2696</identifier><identifier type="local">annrheumdis;72/Suppl_3/A901-c</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource><recordOrigin>© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-BKNCHRHM-0/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001315 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001315 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:D7A53D6078DBDF33541E5A73A1A49B488BC70DDC
|texte= AB0374 End-organ damage in a cohort of filipino patients with systemic lupus erythematosus at two tertiary hospitals
}}
| This area was generated with Dilib version V0.6.33. |  |